Uptake of novel statistical methods for early-phase clinical studies in the UK public sector
Abstract
Background
In recent years, the success rate of confirmatory studies has been poor resulting in more emphasis on the conduct of exploratory studies. As one possibility to improve decision-making during the early stages of development, adaptive and Bayesian methods have been recommended.
Purpose
To investigate the current practice in designing early-phase studies in UK public sector research institutions and the use of adaptive and Bayesian methods in particular and to determine factors that hinder the penetration of methodological advances into practice.
Methods
A questionnaire was sent to all UK clinical trials units (CTUs) to gauge their involvement in early-phase studies and to learn about the designs used in these studies. Follow-up visits to units conducting early-phase studies with round-table discussions around the methods used and the obstacles faced when using adaptive methods were undertaken.
Results
More than half of the CTUs are involved in early-phase studies, but conservatism in the methods used in these studies is present. Reasons for novel methodology not being used include a lack of expertise, incompatible funding and unit structure, and a lack of software.
Limitations
Information is collected from UK CTUs, which undertake a large portion (but not all) publicly funded trials.
Conclusions
The use of adaptive and Bayesian methods for early-phase clinical studies in the UK public sector is at present limited. Various different initiatives aim to support and facilitate the use of these methods, however, so that an increased use of these methods can be anticipated in the future.
Get full access to this article
View all access and purchase options for this article.
References
1. Krams M, Burman C-F, Dragalin V, et al. Adaptive designs in clinical drug development: Opportunities, challenges, and scope reflections following PhRMA’s November 2006 workshop. J Biopharm Stat 2007; 17: 957–64.
2. Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chro Dis 1960; 13: 346–53.
3. Carter SK. Study design principles for the clinical evaluation of new drugs as developed by the chemotherapy programme of the National Cancer Institute. In Staquet MJ (ed.) The Design of Clinical Trials in Cancer Therapy. Futura Publishing Co., Mount Kisco, NY, 1973, pp. 242–89.
4. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1–10.
5. Tighiouart M, Rogatko A, Babb J. Flexible Bayesian methods for cancer phase I clinical trials: Dose escalation with overdose control. Stat Med 2005; 24: 2183–96.
6. Whitehead J, Jaki T. One- and two-stage design proposals for a phase II trial comparing three active treatments with control using an ordered categorical endpoint. Stat Med 2009; 28: 828–47.
7. O’Quigley J, Pepe M, Fisher L. Continual reassessment method: A practical design for phase I clinical trials in cancer. Biometrics 1990; 46: 33–48.
8. Rogatko A, Schoeneck D, Jonas W, et al. Translation of innovative designs into phase I trials. J Clin Oncol 2007; 25: 4982–86.
9. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer trials. J Natl Cancer I 2009; 101: 708–20.
10. Guidance for Industry. Adaptive design clinical trials for drugs and biologics. Draft guidance, February 2010. Available at: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdf
11. Guidance for Industry. Guidance for the use of Bayesian statistics in medical device clinical trials. Guidance, February 2010. Available at: http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm071121.pdf
Cite article
Cite article
Cite article
OR
Download to reference manager
If you have citation software installed, you can download article citation data to the citation manager of your choice
Information, rights and permissions
Information
Published In
Article first published online: February 1, 2013
Issue published: April 2013
PubMed: 23378484
Authors
Metrics and citations
Metrics
Article usage*
Total views and downloads: 187
*Article usage tracking started in December 2016
Altmetric
See the impact this article is making through the number of times it’s been read, and the Altmetric Score.
Learn more about the Altmetric Scores
Articles citing this one
Receive email alerts when this article is cited
Web of Science: 30 view articles Opens in new tab
Crossref: 31
-
Fitting Log-Gaussian Cox Processes Using Generalized Additive Model So...
-
Early phase clinical trials in oncology: Realising the potential of se...
-
SPIRIT and CONSORT extensions for early phase dose-finding clinical tr...
-
Practical recommendations for implementing a Bayesian adaptive phase I...
-
Group sequential designs in pragmatic trials: feasibility and assessme...
-
Practical guidance for planning resources required to support publicly...
-
Bayesian two‐stage design for phase II onc...
-
Costs and staffing resource requirements for adaptive clinical trials:...
-
Would the Recommended Dose Have Been Different Using Novel Dose-Findin...
-
Adding flexibility to clinical trial designs: an example-based guide t...
-
Stakeholder perspectives on adaptive clinical trials: a scoping review
-
A review of available software for adaptive clinical trial design
-
Designing and evaluating dose-escalation studies made easy: The MoDEsT...
-
How to design a dose-finding study using the continual reassessment me...
-
Adaptive designs in clinical trials: why use them, and how to run and ...
-
Development process of a consensus-driven CONSORT extension for random...
-
Revisiting isotonic phase I design in the era of model-assisted dose-f...
-
Ten Essential Practices for Developing or Reforming a Biostatistics Co...
-
Embracing model-based designs for dose-finding trials
-
Dose-finding designs for trials of molecularly targeted agents and imm...
-
Adaptive designs undertaken in clinical research: a review of register...
-
AplusB: A Web Application for Investigating A + B Designs for Phase I ...
-
A review of statistical designs for improving the efficiency of phase ...
-
Pilot Studies in clinical research
-
Missing steps in a staircase: a qualitative study of the perspectives ...
-
Cross-sector surveys assessing perceptions of key stakeholders towards...
-
Reflections on the adaptive designs accelerating promising trials into...
-
Phase 1 trials
-
An investigation of the impact of futility analysis in publicly funded...
-
Reducing the average number of patients needed in a phase II trial thr...
-
Six pairs of things to celebrate on International Clinical Trials Day
Figures and tables
Figures & Media
Tables
View Options
Get access
Access options
If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:
loading institutional access options
SCT members can access this journal content using society membership credentials.
SCT members can access this journal content using society membership credentials.
Alternatively, view purchase options below:
Purchase 24 hour online access to view and download content.
Access journal content via a DeepDyve subscription or find out more about this option.
